Renal Ischemia-Reperfusion Injury (RIRI) Model

Creative Bioarray boasts extensive expertise in conducting preclinical studies on acute kidney injury (AKI) through the use of rodent models. Our team has meticulously crafted a refined model for renal ischemia-reperfusion injury (RIRI), which stands out as a pivotal tool for the meticulous screening, rigorous testing, and comprehensive evaluation of your prospective drug candidates.

The RIRI model simulates the pathological sequence of ischemia/reperfusion injury (IRI), which initially involves a restriction in blood supply to the kidney, subsequently followed by the restoration of blood flow and re-oxygenation. This process, when occurring in the kidney, can lead to AKI, a clinical syndrome characterized by rapid kidney dysfunction and associated with high mortality rates. The cardinal factors that contribute to kidney damage during RIRI include oxidative stress, excessive accumulation of calcium in the cytosol, mitochondrial uncoupling, liberation of iron ions, and the activation of an inflammatory immune response. The RIRI model serves as a valuable tool for studying the mechanisms underlying AKI and evaluating potential therapeutic strategies for its prevention and treatment.

Fig. 1 Mechanisms of renal ischemia-reperfusion injury. (Krzywonos-Zawadzka et al. 2019)

Our Renal Ischemia-Reperfusion Injury Model

• Available Animal

• Rat
• Mouse

• Modeling Method

Animals are fasted for 8-12 hours before surgery. Following anesthesia, a midline incision is made starting from the xiphoid process. The abdominal cavity is then accessed, and the kidney is mobilized and released from its attachments. The renal artery is prepared for complete occlusion using surgical bulldog clips for 45-60 minutes to implement the ischemia-reperfusion protocol.

Fig. 2 Schematic diagram of the method for establishing the RIRI model

• Endpoints

• Serum analysis: BUN, creatinine, etc.
• Histology analysis
• Cytokine analysis
• qPCR or Western blot
• Other customized endpoints

Example Data

Fig. 3 Pioglitazone treatment improves renal IRI. (A) Serum creatinine levels in different groups at 24 h after renal IRI. (B) Serum urea nitrogen levels in different groups at 24 h after renal IRI. (Zou et al. 2021)

Quotation and Ordering

Creative Bioarray provides urological study services, focusing on conducting preclinical efficacy, proof-of-concept, and mechanism of action studies in different rodent models. Our scientists have the necessary skills and experience to evaluate the efficacy of your preclinical drug candidates. If you are interested in our services, please feel free to contact us at any time or submit an inquiry to us directly.

References

1. Zou, G., et al. Pioglitazone ameliorates renal ischemia-reperfusion injury via inhibition of NF-κB activation and inflammation in rats. Frontiers in Physiology, 2021, 12: 707344.
2. Krzywonos-Zawadzka, A., et al. Pharmacological protection of kidney grafts from cold perfusion-induced injury. BioMed Research International, 2019, 2019.

For research use only. Not for any other purpose.